spironolactone has been researched along with Autoimmune Diabetes in 12 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The studies were double-blind, randomised, placebo-controlled studies in 46 type 1 and 23 type 2 diabetic patients with micro- or macroalbuminuria treated with angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB), and randomised to additional treatment with spironolactone 25 mg and placebo daily for 60 days." | 9.17 | Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. ( Nielsen, SE; Parving, HH; Persson, F; Rossing, K; Rossing, P; Schalkwijk, CG; Schjoedt, KJ; Stehouwer, CD, 2013) |
| " We expected an impact of spironolactone in early diabetic nephropathy, and for this hypothesis we studied the effect on markers of glomerular and tubular damage in patients with Type 1 diabetes and persistent microalbuminuria." | 9.16 | Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. ( Frandsen, E; Hess, G; Nielsen, SE; Parving, HH; Persson, F; Rossing, P; Shjoedt, KJ; Sugaya, T; Zdunek, D, 2012) |
| "The studies were double-blind, randomised, placebo-controlled studies in 46 type 1 and 23 type 2 diabetic patients with micro- or macroalbuminuria treated with angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB), and randomised to additional treatment with spironolactone 25 mg and placebo daily for 60 days." | 5.17 | Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. ( Nielsen, SE; Parving, HH; Persson, F; Rossing, K; Rossing, P; Schalkwijk, CG; Schjoedt, KJ; Stehouwer, CD, 2013) |
| " We expected an impact of spironolactone in early diabetic nephropathy, and for this hypothesis we studied the effect on markers of glomerular and tubular damage in patients with Type 1 diabetes and persistent microalbuminuria." | 5.16 | Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. ( Frandsen, E; Hess, G; Nielsen, SE; Parving, HH; Persson, F; Rossing, P; Shjoedt, KJ; Sugaya, T; Zdunek, D, 2012) |
| "Spironolactone did not change the overall ability to autoregulate GFR in 16 hypertensive type 1 diabetic patients with normoalbuminuria." | 5.14 | Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. ( Boomsma, F; Christensen, PK; Jorsal, A; Parving, HH; Rossing, P; Schjoedt, KJ, 2009) |
| "On spironolactone treatment, one patient was excluded due to hyperkalemia (plasma potassium 5." | 2.71 | Beneficial impact of spironolactone in diabetic nephropathy. ( Boomsma, F; Juhl, TR; Parving, HH; Rossing, K; Rossing, P; Schjoedt, KJ; Tarnow, L, 2005) |
| "Type 1 diabetes was induced in female Wistar rats by a single tail vein injection of streptozotocin (STZ), and SPL was administrated daily by gavage, from days 3-21." | 1.46 | Aldosterone signaling regulates the over-expression of claudin-4 and -8 at the distal nephron from type 1 diabetic rats. ( González-Ramírez, R; Molina-Jijón, E; Namorado-Tónix, C; Pedraza-Chaverri, J; Reyes, JL; Rodríguez-Muñoz, R, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Molina-Jijón, E | 1 |
| Rodríguez-Muñoz, R | 1 |
| González-Ramírez, R | 1 |
| Namorado-Tónix, C | 1 |
| Pedraza-Chaverri, J | 1 |
| Reyes, JL | 1 |
| Huynh, T | 1 |
| Harty, BJ | 1 |
| Claggett, B | 1 |
| Fleg, JL | 1 |
| McKinlay, SM | 1 |
| Anand, IS | 1 |
| Lewis, EF | 1 |
| Joseph, J | 1 |
| Desai, AS | 1 |
| Sweitzer, NK | 1 |
| Pitt, B | 1 |
| Pfeffer, MA | 1 |
| Rouleau, JL | 1 |
| Schjoedt, KJ | 3 |
| Christensen, PK | 1 |
| Jorsal, A | 1 |
| Boomsma, F | 2 |
| Rossing, P | 4 |
| Parving, HH | 4 |
| Toba, H | 1 |
| Mitani, T | 1 |
| Takahashi, T | 1 |
| Imai, N | 1 |
| Serizawa, R | 1 |
| Wang, J | 1 |
| Kobara, M | 1 |
| Nakata, T | 1 |
| Nielsen, SE | 2 |
| Persson, F | 2 |
| Frandsen, E | 1 |
| Sugaya, T | 1 |
| Hess, G | 1 |
| Zdunek, D | 1 |
| Shjoedt, KJ | 1 |
| Rossing, K | 2 |
| Schalkwijk, CG | 1 |
| Stehouwer, CD | 1 |
| Juhl, TR | 1 |
| Tarnow, L | 1 |
| Guo, C | 1 |
| Martinez-Vasquez, D | 1 |
| Mendez, GP | 1 |
| Toniolo, MF | 1 |
| Yao, TM | 1 |
| Oestreicher, EM | 1 |
| Kikuchi, T | 1 |
| Lapointe, N | 1 |
| Pojoga, L | 1 |
| Williams, GH | 1 |
| Ricchiuti, V | 1 |
| Adler, GK | 2 |
| Epstein, M | 1 |
| Joffe, HV | 1 |
| Kwong, RY | 1 |
| Gerhard-Herman, MD | 1 |
| Rice, C | 1 |
| Feldman, K | 1 |
| Large, DM | 1 |
| Carr, PH | 1 |
| Laing, I | 1 |
| Davies, M | 1 |
| Hancock, EW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Spironolactone in Diabetic Nephropathy[NCT00317954] | Phase 4 | 48 participants | Interventional | 2003-09-30 | Completed | ||
| Aldosterone and Vascular Disease in Diabetes Mellitus[NCT00214825] | 46 participants (Actual) | Interventional | 2003-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for spironolactone and Autoimmune Diabetes
| Article | Year |
|---|---|
Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study).
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Heart Fail | 2019 |
Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial.
Topics: Adult; Aged; Albuminuria; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blin | 2009 |
Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin Receptor Antagonists; Angiotens | 2012 |
Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease.
Topics: Albuminuria; Biomarkers; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; End | 2013 |
Beneficial impact of spironolactone in diabetic nephropathy.
Topics: Adult; Aldosterone; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; H | 2005 |
Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Brachia | 2007 |
6 other studies available for spironolactone and Autoimmune Diabetes
| Article | Year |
|---|---|
Aldosterone signaling regulates the over-expression of claudin-4 and -8 at the distal nephron from type 1 diabetic rats.
Topics: Aldosterone; Animals; Claudin-4; Claudins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2017 |
Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetes.
Topics: Aldosterone; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropat | 2010 |
Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.
Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 2006 |
Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy.
Topics: Adult; Aldosterone; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; H | 2006 |
Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 1; Female; Humans; Hyperkalemia; Male; Middle Aged; Reni | 1984 |
Normal ECG or peaked T waves?
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Diabetes Mell | 1998 |